SCHEMBL264408

SCHEMBL264408

O=C(Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.59
HIF1A Q16665 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733367 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL29674600 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL21539907 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL264409 1.00 SLC29A1 (0.59) SLC29A1HIF1A
SCHEMBL22984010 1.00 SLC29A1 (0.59) SLC29A1HIF1A
Water SCHEMBL29821265 0.99 SLC29A1 (0.58) SLC29A1HIF1A
SCHEMBL23881920 0.92 SLC29A1 (0.49) SLC29A1HIF1A
SCHEMBL31093228 0.92 SLC29A1 (0.49) SLC29A1
SCHEMBL9342970 0.92 SLC29A1 (0.49) SLC29A1HIF1A
SCHEMBL9342988 0.92 SLC29A1 (0.49) SLC29A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4606903-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION Asymchem Life Science (Tianjin) Co., Ltd (CN) 2025-08-27 EP claimed
CN-118956882-A Aptamer containing modified base and application thereof 焕生汇生物基因技术(北京)有限公司 2024-11-15 CN claimed
CN-118666926-A Glycosyl phosphoramidite monomer, preparation method thereof and synthesis method of glycosyl oligonucleotide 上海交通大学医学院附属仁济医院 2024-09-20 CN claimed
WO-2024082545-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION 凯莱英生命科学技术(天津)有限公司 2024-04-25 WO claimed
CN-115181147-B Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid 南开大学 2024-04-02 CN claimed
CN-116064703-A Method and composition for enzymatic synthesis of nucleosides containing protecting groups 凯莱英生命科学技术(天津)有限公司 2023-05-05 CN claimed
CN-115181147-A Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid 南开大学 2022-10-14 CN claimed
CN-114369123-A Efficient preparation method of 5' -aminodeoxynucleoside 山东明化新材料有限公司 2022-04-19 CN claimed
CN-105968016-A Carbonic ester type photosensitive reagent and preparation method thereof as well as preparation method of 5'-photolabile dN 石平 2016-09-28 CN claimed
CN-104628574-A Carbonate photosensitive reagent, preparation method thereof and preparation method of 5' -photosensitive protection nucleoside SHI PING 2015-05-20 CN claimed
WO-2000075154-A2 PROTECTED NUCLEOSIDES ALLIEDSIGNAL INC. (US) 2000-12-14 WO claimed
EP-0548189-B1 A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE STERLING WINTHROP INC (US) 1994-12-28 EP claimed
EP-4748940-A2 DE NOVO SYNTHESISED GENE LIBRARIES Twist Bioscience Corporation (US) 2026-05-27 EP disclosed
US-20260138111-A1 DE NOVO SYNTHESIZED GENE LIBRARIES Twist Bioscience Corporation (US) 2026-05-21 US disclosed
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 EP disclosed
US-12569822-B2 De novo synthesized gene libraries Twist Bioscience Corporation (US) 2026-03-10 US disclosed
US-4457867-A VIRICIDES, ANTITUMOR ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1984-07-03 US disclosed
EP-0083777-A1 Physiologically active peptide with between 147 and 162 amino acid residues Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1983-07-20 EP disclosed
EP-0064796-A2 Phosphorylating agent and process for the phosphorylation of organic hydroxyl compounds UNILEVER N.V. (NL) 1982-11-17 EP disclosed
EP-0061746-A1 Phosphoramidite compounds and their use in producing oligonucleotides UNIVERSITY PATENTS, INC. (US) 1982-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138111-A1 DE NOVO SYNTHESIZED GENE LIBRARIES POLM, DNMT3A, POLN SLC29A1 160/4885HIF1A 4431/4885
US-12569822-B2 De novo synthesized gene libraries POLM, NSUN2, POLL SLC29A1 356/4885HIF1A 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.